

Asst. Prof. KÜBRA ÇALIŞKAN

Personal Information

Office Phone: [+90 312 202 3226](tel:+903122023226)

Email: kubraibis@gazi.edu.tr

Other Email: kub.ibis1992@gmail.com

Web: <https://avesis.gazi.edu.tr/kubraibis>

International Researcher IDs

ScholarID: -cVg9HMAAAAJ

ORCID: 0000-0002-6898-0258

Publons / Web Of Science ResearcherID: AHA-8168-2022

ScopusID: 57204017714

Education Information

Doctorate, Gazi University, Sağlık Bilimleri Enstitüsü, Turkey 2015 - 2020

Undergraduate, Gazi University, Eczacılık Fakültesi, Turkey 2010 - 2015

Dissertations

Doctorate, Yeni izoksazol türevlerinin sentezi, karaciğer ve meme kanseri hücre hatlarına karşı sitotoksik etkilerinin incelenmesi, Gazi University, Sağlık Bilimleri Enstitüsü, 2020

Research Areas

Health Sciences, Pharmacology and Therapeutics, Pharmaceutical Chemistry

Academic Titles / Tasks

Lecturer PhD, Gazi University, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri, 2021 - Continues

Published journal articles indexed by SCI, SSCI, and AHCI

- Tirbanibulin (KX2-391) analog KX2-361 inhibits botulinum neurotoxin serotype A mediated SNAP-25 cleavage in pre- and post-intoxication models in cells**
Koc D., ÇALIŞKAN K., Besarat P., BANOĞLU E., KİRİŞ E.
Drug Development Research, vol.85, no.6, 2024 (SCI-Expanded)
- Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer**
Gedik M. E., Saatci O., Oberholtzer N., ÜNER M., Akbulut Caliskan O., Cetin M., Aras M., ÇALIŞKAN K., ÇALIŞKAN B., BANOĞLU E., et al.
Cancer research, vol.84, no.9, pp.1475-1490, 2024 (SCI-Expanded)
- Benzoxazolone-5-Urea Derivatives as Human Soluble Epoxide Hydrolase (sEH) Inhibitors.**

- Gür Maz Z. T., Koç B., Jordan P. M., İbiş K., Çalışkan B., Werz O., Banoğlu E.
ACS OMEGA, vol.8, no.2, pp.2445-2454, 2023 (SCI-Expanded)
- IV. **The 1,2,3-triazole 'all-in-one' ring system in drug discovery: a good bioisostere, a good pharmacophore, a good linker, and a versatile synthetic tool.**
Lengerli D., Ibis K., Nural Y., Banoglu E.
Expert opinion on drug discovery, vol.17, no.11, pp.1209-1236, 2022 (SCI-Expanded)
- V. **Vicinal Diaryl-Substituted Isoxazole and Pyrazole Derivatives with in Vitro Growth Inhibitory and in Vivo Antitumor Activity**
Turanlı S., NALBAT E., LENERLİ D., İBİŞ K., Güntekin Ergün S., Akhan Güzelcan E., MUYAN M., Cetin-Atalay R., Çalışkan B., BANOĞLU E.
ACS Omega, vol.7, no.41, pp.36206-36226, 2022 (SCI-Expanded)
- VI. **Synthesis and biological evaluation of novel isoxazole-piperazine hybrids as potential anti-cancer agents with inhibitory effect on liver cancer stem cells**
Ibis K., NALBAT E., ÇALIŞKAN B., KAHRAMAN D. C., Cetin-Atalay R., BANOĞLU E.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol.221, 2021 (SCI-Expanded)
- VII. **Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents**
ÇALIŞKAN B., NALBAT E., Ibis K., Guzelcan E. A., ATALAY R., BANOĞLU E.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, vol.33, no.1, pp.1352-1361, 2018 (SCI-Expanded)

Refereed Congress / Symposium Publications in Proceedings

- I. **SYNTHESIS, BIOLOGICAL EVALUATION AND MOLECULAR DOCKING STUDIES OF NEW 1-(2-CHLOROPHENYL)UREA DERIVATIVES AS INHIBITORS OF HUMAN SOLUBLE EPOXIDE HYDROLASE**
İbiş K.
International Multidisciplinary Symposium on Drug Research and Development (DRD) 2023, İzmir, Turkey, 4 - 06 May 2023, pp.204
- II. **DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL IMIDAZOLIDINONE-THIAZOLE AMIDE HYBRIDS AS INHIBITORS OF HUMAN SOLUBLE EPOXIDE HYDROLASE**
İbiş K., Lengerli D., Jordan P. M., Çalışkan B., Werz O., Banoğlu E.
9th EFMC Young Medicinal Chemists' Symposium, Nice, France, 8 - 09 September 2022
- III. **KARACIĞER KANSERİ KÖK HÜCRELERİ ÜZERİNDE İNHİBİTÖR ETKİYE SAHİP, POTANSİYEL ANTİKANSER AJANLAR OLARAK YENİ İZOKSAZOL-PIPERAZİN HİBRİTLERİNİN SENTEZİ VE BİYOLOJİK OLARAK DEĞERLENDİRİLMESİ**
İbiş K., Nalbat E., Çalışkan B., Atalay R., Banoğlu E.
VI. Ulusal Farmasötik Kimya Kongresi, İstanbul, Turkey, 26 - 29 August 2022
- IV. **Novel isoxazole- piperazine derivatives inhibit the stemness of HCC cells**
NALBAT E., İBİŞ K., ÇALIŞKAN B., BANOĞLU E., ATALAY M. V., ATALAY R.
AASLD-TASL Digital Hepatology Meeting, Ankara, Turkey, 15 January 2022, pp.5-6
- V. **SYNTHESIS AND ANTIPROLIFERATIVE EVALUATION OF NOVEL ISOXAZOLE-PIPERAZINE HYBRIDS**
ÇALIŞKAN B., Sinoplu E., İbiş K., AKHAN GÜZELCAN E., ATALAY R., BANOĞLU E.
RICT 2018, 4 - 06 July 2018
- VI. **SYNTHESIS, CYTOTOXICITY AND STRUCTURE-ACTIVITYRELATIONSHIPS OF NOVEL ISOXAZOLE DERIVATIVES ASANTICANCER AGENTS**
İbiş K., ÇALIŞKAN B., AKHAN GÜZELCAN E., Sinoplu E., ATALAY R., BANOĞLU E.
RICT 2018, 4 - 06 July 2018
- VII. **Discovery and Development of Novel Anti-cancer and Anti-inflammatory Compounds: Medicinal Chemistry Challenges**
BANOĞLU E., ÇALIŞKAN B., GÜR MAZ Z. T., OLĞAÇ A., İBİŞ K., Akhan Güzelcam E., Sinoplu E., Garscha U., Gerstmeier

Supported Projects

ÇALIŞKAN K., Project Supported by Higher Education Institutions, Yeni 1,5-Diarilpirazol-3-karboksamit Türevlerinin Sentezi ve Antikanser Aktivitelerinin İncelenmesi, 2024 - Continues

BANOĞLU E., TUĞCU DEMİRÖZ F. N., ÇALIŞKAN K., YILDIZ A., AKKOL E., BAYTAŞ S., TIRNAKSIZ F. F., ŞATANA KARA H. E., KARAHALİL B., ER DEMİRHAN B., et al., Project Supported by Higher Education Institutions, YENİ İLAÇ AKTİF MADDESİ KEŞİF GELİŞTİRME VE BİYOLOJİK ETKİNLİKLERİNİN DEĞERLENDİRİLMESİ ÜZERİNE ÇALIŞMALAR, 2024 - Continues

GÜR MAZ Z. T., BANOĞLU E., KOÇ B., ÇALIŞKAN B., İBİŞ K., WERZ O., JORDAN P. M., Project Supported by Higher Education Institutions, Bazı Yeni İndol Türevi Çözünür Epoksit Hidrolaz İnhibitörlerinin Geliştirilmesi Üzerine Çalışmalar, 2024 - Continues

ÇALIŞKAN K., KARATAŞ M., JORDAN P. M., BANOĞLU E., ÇALIŞKAN B., WERZ O., Project Supported by Higher Education Institutions, Dual FLAP/sEH İnhibitörlerinin Geliştirilmesi Üzerine Çalışmalar, 2023 - Continues

BANOĞLU E., WERZ O., NALBAT E., TURANLI S., ÇALIŞKAN B., İBİŞ K., Project Supported by Higher Education Institutions, Yeni Kinazolinon Türevi Çözünür Epoksit Hidrolaz (sEH) İnhibitörlerinin Geliştirilmesi, 2021 - 2024

Banoğlu E., Çalışkan B., TUBITAK Project, Meme ve Karaciğer Kanserin Tedavisi için PI3K/Akt Sinyal Yolunu Hedefleyen Yeni Aday İlaç Molekül Geliştirme ve Ön klinik Çalışmaları, 2016 - 2019

Banoğlu E., Çalışkan B., TUBITAK Project, INVESTIGATIONS ON THE SYNTHESIS, STRUCTURE-ACTIVITY RELATIONSHIPS AND MECHANISMS OF ACTION OF NOVEL ISOXAZOLE DERIVATIVES WITH POTENTIAL ANTICANCER ACTIVITY, 2015 - 2018

Patent

Banoğlu E., Çalışkan B., Lengerli D., Çalışkan K., Şahin Ö., Lim C., Cruz E., Vempati S., EP22788722 COMPOSITIONS AND METHODS FOR TREATING CANCER, Patent, CHAPTER A Human Needs, The Invention Recourse Number: EP/22788722.1 , Standard Registration, 2023

Banoğlu E., Çalışkan B., Lengerli D., Çalışkan K., Şahin Ö., Lim C., Cruz E., Vempati S., AU2022256380 COMPOSITIONS AND METHODS FOR TREATING CANCER , Patent, CHAPTER A Human Needs, The Invention Recourse Number: 2022256380 , Standard Registration, 2023

Banoğlu E., Çalışkan B., Lengerli D., Çalışkan K., Şahin Ö., Lim C., Cruz E., Vempati S., CA3216541 COMPOSITIONS AND METHODS FOR TREATING CANCER, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 3216541 , Standard Registration, 2023

Banoğlu E., Çalışkan B., Lengerli D., Çalışkan K., Şahin Ö., Akbulut B., Lim C., Cruz E., Vempati S., HK62023072323.6 ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 62023072323.6 , Standard Registration, 2023

Banoğlu E., Çalışkan B., Muyan M., Atalay R., Erson Bensan A. E., Lengerli D., Güntekin S., Turanlı S., İbiş K., ANTİKANSER AKTİVİTEYE SAHİP YENİ VİSİNAL DİARİL HETEROSİKLİK BİLEŞİK TÜREVLERİ, Patent, CHAPTER A Human Needs, The Invention Registration Number: TR 2019 14610 B , Standard Registration, 2023

Banoğlu E., Çalışkan B., Lengerli D., Çalışkan K., Şahin Ö., Lim C., Cruz E., Vempati S., CN202280041301.1 COMPOSITIONS AND METHODS FOR TREATING CANCER, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 202280041301.1 , Standard Registration, 2023

Banoğlu E., Çalışkan B., Lengerli D., Çalışkan K., Şahin Ö., Lim C., Cruz E., Vempati S., NZ805433 COMPOSITIONS AND METHODS FOR TREATING CANCER , Patent, CHAPTER A Human Needs, The Invention Recourse Number: 805433 , Standard Registration, 2023

Banoğlu E., Çalışkan B., Lengerli D., Çalışkan K., Şahin Ö., Lim C., Cruz E., Vempati S., JP562485 COMPOSITIONS AND METHODS FOR TREATING CANCER , Patent, CHAPTER A Human Needs, The Invention Recourse Number: 2023-562485 , Standard Registration, 2023

Banođlu E., alıřkan B., Lengerli D., alıřkan K., řahin ., Lim C., Cruz E., Vempati S., KR10-2023-7038832 COMPOSITIONS AND METHODS FOR TREATING CANCER , Patent, CHAPTER A Human Needs, The Invention Recourse Number: 10-2023-7038832 , Standard Registration, 2023

Banođlu E., alıřkan B., Lengerli D., alıřkan K., řahin ., Lim C., Cruz E., Vempati S., US18/286469 COMPOSITIONS AND METHODS FOR TREATING CANCER , Patent, CHAPTER A Human Needs, The Invention Recourse Number: 18/286469 , Standard Registration, 2023

Banođlu E., alıřkan B., Lengerli D., alıřkan K., řahin ., Lim C., Cruz E., Vempati S., IN202327073452 COMPOSITIONS AND METHODS FOR TREATING CANCER, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 202327073452 , Standard Registration, 2023

Banođlu E., alıřkan B., Lengerli D., İbiř K., řahin ., Lim C., Cruz E., Vempati S., TW111113780-COMPOSITIONS AND METHODS FOR TREATING CANCER, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 111113780 , Standard Registration, 2022

Banođlu E., alıřkan B., Lengerli D., İbiř K., řahin ., Akbulut ., Vempati S., Lim C., Cruz E., KR10-2022-7020047-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: KR10-2022-7020047 , Standard Registration, 2022

Banođlu E., alıřkan B., Lengerli D., İbiř K., řahin ., Akbulut ., Vempati S., Lim C., Cruz E., CN 202080091759.9 (2022110200431050)-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: CN 115279754 A (2022072000921700) , Standard Registration, 2022

Banođlu E., alıřkan B., İbiř K., Lengerli D., řahin ., Akbulut ., Lim C., Cruz E., Vempati S., JP2022-527677-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 2022-527677 , Standard Registration, 2022

Banođlu E., alıřkan B., İbiř K., Lengerli D., řahin ., Akbulut ., Lim C., Cruz E., Vempati S., EP20888312.4-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: EP/20888312.4 , Standard Registration, 2022

Banođlu E., alıřkan B., Lengerli D., İbiř K., řahin ., Vempati S., Lim C., Cruz E., PCT/US2022/024263 (WO2022/221194 A1) COMPOSITIONS AND METHODS FOR TREATING CANCER, Patent, CHAPTER A Human Needs, The Invention Recourse Number: US22/24263 , Standard Registration, 2022

Banođlu E., alıřkan B., Lengerli D., İbiř K., řahin ., Akbulut ., Lim C., Vempati S., Cruz E., US17/776,767-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: US17/776,767 , Standard Registration, 2022

Banođlu E., alıřkan B., Lengerli D., İbiř K., řahin ., Lim C., Cruz E., Vempati S., COMPOSITIONS AND METHODS FOR TREATING CANCER, Patent, CHAPTER A Human Needs, The Invention Recourse Number: US63173796 , 2021

Banođlu E., alıřkan B., Atalay R., Akhan Gzelcan E., İbiř K., ANTİKANSER AKTİVİTEYE SAHİP YENİ İZOKSAZOL TREVLERİ, Patent, CHAPTER A Human Needs, The Invention Registration Number: 2017 19951 , Standard Registration, 2021

Banođlu E., alıřkan B., Lengerli D., İbiř K., řahin ., Akbulut ., Lim C., Vempati S., Cruz E., ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS (US/PCT), Patent, CHAPTER A Human Needs, The Invention Recourse Number: PCT/US/2020/060588 , 2020

Metrics

Publication: 14

Citation (WoS): 84

Citation (Scopus): 101

H-Index (WoS): 3

H-Index (Scopus): 4